Table 1.
Relationship between metabolic markers and clinicopathologic features in patients with non-small cell lung carcinoma.
| GLUT1 | GLUT3 | FDG-PET SUVmax | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Negative (n = 41) | Positive (n = 122) |
p | Negative (n = 153) | Positive (n = 10) |
P | Low (<7) (n = 99) | High (≥7) (n = 64) |
p | |
| Age (years) | 63.2 ± 9.4 | 65.3 ± 10.1 | 0.236 | 64.6 ± 9.8 | 67.7 ± 11.9 | 0.337 | 63.7 ± 9.7 | 66.5 ± 10.1 | 0.082 |
| Sex | |||||||||
| Male (n = 111, 68.1%) | 17 (41.5%) | 94 (77.0%) | <0.001 | 103 (67.3%) | 8 (80%) | 0.629 | 58 (58.6%) | 53 (82.8%) | 0.002 |
| Female (n = 52, 31.9%) | 24 (58.5%) | 28 (23.0%) | 50 (32.7%) | 2 (20%) | 41 (41.4%) | 11 (17.2%) | |||
| Smoking Status | |||||||||
| Never smoker (n = 71, 43.6%) | 27 (65.9%) | 44 (36.1%) | 0.002 | 67 (43.8%) | 4 (40%) | 0.999 | 53 (53.5%) | 18 (28.1%) | 0.002 |
| Ever smoker (n = 92, 56.4%) | 14 (34.1%) | 78 (63.9%) | 86 (56.2%) | 6 (60%) | 46 (46.5%) | 46 (71.9%) | |||
| Histology | |||||||||
| Non-SqCC (n = 115 70.6%) | 40 (97.6%) | 75 (61.5%) | <0.001 | 106 (69.3%) | 8 (80%) | 0.719 | 80 (80.8%) | 34 (53.1%) | <0.001 |
| SqCC (n = 48, 29.4%) | 1 (2.44%) | 47 (38.5%) | 47 (30.7%) | 2 (20%) | 19 (19.2%) | 30 (46.9%) | |||
| Tumor differentiation | |||||||||
| WD and MD (n = 133, 81.6%) | 39 (95.1%) | 94 (77.0%) | 0.019 | 127 (83.0%) | 6 (60%) | 0.162 | 87 (87.9%) | 46 (71.9%) | 0.018 |
| PD (n = 30, 18.4%) | 2 (4.88%) | 28 (23.0%) | 26 (17.0%) | 4 (40%) | 12 (12.1%) | 18 (28.1%) | |||
| Lymphovascular invasion | |||||||||
| Absent (n = 125, 76.7%) | 34 (82.9%) | 91 (74.6%) | 0.380 | 117 (76.5%) | 8 (80.0%) | 0.999 | 77 (77.8%) | 48 (75.0%) | 0.826 |
| Present (n = 38, 23.3%) | 7 (17.1%) | 31 (25.4%) | 36 (23.5%) | 2 (20.0%) | 22 (22.2%) | 16 (25.0%) | |||
| T stage * | |||||||||
| 1 (n = 50, 30.7%) | 18 (46.2%) | 32 (32.3%) | 0.129 | 50 (38.2%) | 0 | 0.164 | 40 (46.5%) | 10 (19.2%) | 0.007 |
| 2 (n = 66, 40.5%) | 19 (48.7%) | 47 (47.5%) | 60 (45.8%) | 6 (85.7%) | 37 (43.0%) | 29 (55.8%) | |||
| 3 (n = 18, 6.7%) | 2 (5.1%) | 16 (16.2%) | 17 (13.0%) | 1 (14.3%) | 7 (8.1%) | 11 (21.2%) | |||
| 4 (n = 4, 2.5%) | 0 | 4 (4.0%) | 4 (3.1%) | 0 | 2 (2.3%) | 2 (3.8%) | |||
| N stage † | |||||||||
| 0 (n = 77, 47.2%) | 26 (66.7%) | 51 (52.0%) | 0.139 | 72 (55.4%) | 5 (71.4%) | 0.558 | 52 (61.2%) | 25 (48.1%) | 0.37 |
| 1 (n = 30, 18.4%) | 6 (15.4%) | 24 (24.5%) | 28 (21.5%) | 2 (28.6%) | 16 (18.8%) | 14 (26.9%) | |||
| 2 (n = 29, 17.8%) | 6 (15.4%) | 23 (23.5%) | 29 (22.3%) | 0 | 16 (18.8%) | 13 (25.0%) | |||
| 3 (n = 1, 0.6%) | 1 (2.6%) | 0 | 1 (0.8%) | 0 | 1 (1.2%) | 0 | |||
| AJCC Stage | |||||||||
| I (n = 62, 38.0%) | 22 (53.7%) | 40 (32.8%) | 0.084 | 58 (37.9%) | 4 (40.0%) | 0.302 | 47 (47.5%) | 15 (23.4%) | 0.022 |
| II (n = 41, 25.2%) | 9 (22.0%) | 32 (26.2%) | 38 (24.8%) | 3 (30.0%) | 21 (21.2%) | 20 (31.2%) | |||
| III (n = 34, 20.9%) | 7 (17.1%) | 27 (22.1%) | 34 (22.2%) | 0 | 18 (18.2%) | 16 (25.0%) | |||
| IV (n = 30, 18.4%) | 3 (7.3%) | 23 (18.9%) | 23 (15.0%) | 3 (30.0%) | 13 (13.1%) | 13 (20.3%) | |||
| SUVmax | 4.2 ± 2.9 | 7.1 ± 3.8 | <0.001 | 6.3 ± 3.8 | 8.1 ± 3.5 | 0.157 | - | - | - |
| NLR | 2.9 ± 3.4 | 2.8 ± 2.9 | 0.915 | 2.9 ± 3.1 | 2.6 ± 1.3 | 0.579 | 2.5 ± 2.6 | 3.4 ± 3.4 | 0.091 |
| PLR | 120.8 ± 57.8 | 138.1 ± 91.9 | 0.16 | 131.8 ± 85.8 | 164.3 ± 64.5 | 0.241 | 119.2 ± 60.4 | 156.4 ± 109.4 | 0.015 |
| LMR | 4.4 ± 1.7 | 3.9 ± 1.8 | 0.148 | 4.1 ± 1.8 | 3.2 ± 1.1 | 0.12 | 4.2 ± 1.6 | 3.7 ± 2.1 | 0.085 |
SqCC, squamous cell carcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; AJCC, American Joint Committee on Cancer; SUVmax, maximum standardized uptake value; NLR, Neutrophil–lymphocyte ratio; PLR, Platelet–lymphocyte ratio; LMR, Lymphocyte–monocyte ratio. * Twenty-five patients have missing pathologic T stage data. † Twenty-six patients have missing pathologic N stage data.